Across TCGA pan-cancer cohorts, GOLM1 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated GOLM1 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher GOLM1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GOLM1 expression acts as an unfavorable survival marker.
KIRC are the cancer types where GOLM1 Mutation most reproducibly stratifies survival.